Increased Prevalence of Eosinophilic Esophagitis in Patients With Chronic Rhinosinusitis

Simmons, Jordan K.; Leiman, David A.; Patil, Sarita U.; McCoul, Edward D.; Chen, Philip G.; Tang, Dennis M.; Kuan, Edward C.; Chang, Elena E.; Wu, Arthur W.

doi:10.1177/19458924221116162

Cited by 7 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was discussion on the association of other type-2 inflammatory diseases than asthma as a criterion for indication for biologic treatment. Although biologics have been shown to be effective in many forms of type-2 disease (9,24) , the lack of association between CRSwNP and allergic rhinitis (1) and the inconclusive data on the association between CRSwNP and atopic dermatitis or eosinophilic oesophagitis (1,(25)(26)(27)(28) , led to the decision not to include other type-2 inflammatory diseases in the criteria.…”

Section: Epos2020 Criteriamentioning

confidence: 99%

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

Fokkens¹,

Viskens²,

Backer³

et al. 2023

Rhin

View full text Add to dashboard Cite

Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of responders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Furthermore, gaps in the current knowledge and unmet needs were discussed.

show abstract

Section: Epos2020 Criteriamentioning

confidence: 99%

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

Fokkens¹,

Viskens²,

Backer³

et al. 2023

Rhin

View full text Add to dashboard Cite

show abstract

“…Open access dermatitis 24 and eosinophilic esophagitis. 25 To date, three biologics have been assessed and approved by the European Union for managing severe CRSwNP, [26][27][28] after being studied for asthma: omalizumab, an IgE antibody 29 ; dupilumab, an anti-interleukin (IL)-4-α chain receptor 30 ; and mepolizumab, an IL-5 antagonist. 31 In France, only dupilumab and mepolizumab are reimbursed in case of severe uncontrolled CRSwNP despite the use of nasal and systemic corticosteroid and endoscopic sinus surgery.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey

Favier,

Daveau,

Carsuzaa

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionChronic rhinosinusitis with nasal polyps (CRSwNP) is a frequent condition affecting approximately 2% of the population. Medical treatment consists long-term use of intranasal corticosteroids and short-term use of oral corticosteroids, in adjunct with saline solution rinses. Surgical management is proposed in patients who failed after medical treatment. In France, two biologics are reimbursed in case of severe uncontrolled CRSwNP despite medical treatment and endoscopic sinus surgery. Waiting for head-to-head biologics comparison, studies should report the efficacy and safety of biologics in large real-life cohorts. This study protocol describes the aims and methods of a prospective, observational, national, multicentric cohort of patients with CRSwNP treated with biologics.Methods and analysisThe BIOlogics in severe nasal POlyposis SurvEy is a French multicentre prospective observational cohort study. The main aim is to assess the efficacy and tolerance of biologics in patients with CRSwNP, with or without association with other type 2 diseases, and to determine the strategies in case of uncontrolled disease under biologics. Patients over 18 years old requiring biologics for CRSwNP in accordance with its marketing approval in France (ie, severe nasal polyposis, with lack of control under nasal corticosteroid, systemic corticosteroids and surgery) are invited to participate. Collected data include topical history of surgical procedures and biologics, medication and use of systemic corticosteroids, visual analogical scales for specific symptoms, Sino-Nasal Outcome Test-22 questionnaire, nasal polyp score, asthma control test, Lund-Mackay score on CT scan and IgE concentration and eosinophilic count on blood sample.Trial registrationNCT05228041/DRI_2021/0030.

show abstract

“…Brant et al [200], 2021; Dhar et al [201], 2019; Egede et al [202], 2021; Kukhareva et al [203], 2022; Mahajan et al [204], 2022; Manzar [205], 2022; McCarthy et al [206], 2021; Mehta et al [207], 2018; Nasehi et al [208], 2018; Patil et al [209], 2022; Reddy et al [210], 2021; Renjithlal et al [211], 2022; Torres et al [212], 2023 Adult Dinesh et al [213], 2021; Harbison and Gillan [214], 2018; Khanna et al [215], 2021; McCain et al [216], 2022; Rajamani et al [217], 2015; Simmons et al [218], 2022…”

Section: Population Healthmentioning

confidence: 99%

Use of Epic Electronic Health Record System for Health Care Research: Scoping Review

Chishtie,

Sapiro,

Wiebe

et al. 2023

J Med Internet Res

View full text Add to dashboard Cite

Background Electronic health records (EHRs) enable health data exchange across interconnected systems from varied settings. Epic is among the 5 leading EHR providers and is the most adopted EHR system across the globe. Despite its global reach, there is a gap in the literature detailing how EHR systems such as Epic have been used for health care research. Objective The objective of this scoping review is to synthesize the available literature on use cases of the Epic EHR for research in various areas of clinical and health sciences. Methods We used established scoping review methods and searched 9 major information repositories, including databases and gray literature sources. To categorize the research data, we developed detailed criteria for 5 major research domains to present the results. Results We present a comprehensive picture of the method types in 5 research domains. A total of 4669 articles were screened by 2 independent reviewers at each stage, while 206 articles were abstracted. Most studies were from the United States, with a sharp increase in volume from the year 2015 onwards. Most articles focused on clinical care, health services research and clinical decision support. Among research designs, most studies used longitudinal designs, followed by interventional studies implemented at single sites in adult populations. Important facilitators and barriers to the use of Epic and EHRs in general were identified. Important lessons to the use of Epic and other EHRs for research purposes were also synthesized. Conclusions The Epic EHR provides a wide variety of functions that are helpful toward research in several domains, including clinical and population health, quality improvement, and the development of clinical decision support tools. As Epic is reported to be the most globally adopted EHR, researchers can take advantage of its various system features, including pooled data, integration of modules and developing decision support tools. Such research opportunities afforded by the system can contribute to improving quality of care, building health system efficiencies, and conducting population-level studies. Although this review is limited to the Epic EHR system, the larger lessons are generalizable to other EHRs.

show abstract

Increased Prevalence of Eosinophilic Esophagitis in Patients With Chronic Rhinosinusitis

Cited by 7 publications

References 12 publications

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey

Use of Epic Electronic Health Record System for Health Care Research: Scoping Review

Contact Info

Product

Resources

About